834 related articles for article (PubMed ID: 30733722)
1. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
2. Very Low Numbers of CD4
Copsel S; Wolf D; Kale B; Barreras H; Lightbourn CO; Bader CS; Alperstein W; Altman NH; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1788-1794. PubMed ID: 29751114
[TBL] [Abstract][Full Text] [Related]
3. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
4. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
[TBL] [Abstract][Full Text] [Related]
6. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
7. IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
Colonna L; Florek M; Leveson-Gower DB; Sega EI; Baker J; Smith AT; Negrin RS
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1557-65. PubMed ID: 23921175
[TBL] [Abstract][Full Text] [Related]
8. Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.
Mavers M; Simonetta F; Nishikii H; Ribado JV; Maas-Bauer K; Alvarez M; Hirai T; Turkoz M; Baker J; Negrin RS
Front Immunol; 2019; 10():1624. PubMed ID: 31379829
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
10. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
[TBL] [Abstract][Full Text] [Related]
11. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
12. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
13. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
15. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
16. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
17. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
18. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
Lim DG; Koo SK; Park YH; Kim Y; Kim HM; Park CS; Kim SC; Han DJ
Transplantation; 2010 Apr; 89(8):928-36. PubMed ID: 20305583
[TBL] [Abstract][Full Text] [Related]
20. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
